Larimar Therapeutics, Inc.
LRMR
NASDAQ·Healthcare·Biotechnology·Mkt cap $397.9M
$3.83
▲ 0.00%
P/E
-1.92
Mkt Cap
$397.9M
52-Wk Range
$2.72–$6.42
52-Week Range
$2.72 - $6.42
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 2.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary cell penetrating peptide technology platform enabling novel therapeutic approaches
- Orphan drug designation for CTI-1601 providing regulatory advantages and market exclusivity
- Focus on rare genetic diseases with limited treatment options and high unmet medical needs
- Early-stage pipeline positioned for potential expansion into additional rare disease indications
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Advancement of CTI-1601 through Phase 1 and subsequent clinical trial phases
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+23.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LRMR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 4, 2026
Reported EPS of -$0.30 vs -$0.38 consensus (+21.4% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+21.4%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Jun 30, 2026
vs Industry
How LRMR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related